Following the completion of their optometry honours research project on castor oil as a topical blepharitis treatment, University of Auckland now-graduated students Marna Claassen, Alice Jackson and
A Harvard Medical School Schepens Eye Research Institute study has found there’s no benefit to yellow lenses for night driving and they may actually hinder driver reaction times.Published in Jama
Since completing her work as vice-chair of TFOS DEWS II and initiating a plethora of significant research at home and in collaboration with several overseas institutions through the Ocular Surface
The jungles of Borneo are the destination for next year’s specialist study trip by Jon Baines Tours, which provides eye-related education amid exotic travel experiences.Home to at least 26 indigenous
Researchers from the University of Pennsylvania have created an eye-on-a-chip with a mechanical eyelid simulating blinking to test experimental drugs for dry eye disease (DED).The research, published
Validated questionnaires are routinely used to screen for symptoms of dry eye disease prior to the clinical evaluation of ocular surface and tear film parameters. The recent TFOS DEWS II Diagnostic
A first-of-its-kind robotic contact lens created by scientists in San Diego zooms with the blink of an eye.The new biomimetic soft lens, controlled by electrooculographic (EOG) signal, has been
The Ocular Surface Laboratory (OSL) is continuing its endeavours into shedding light on the natural history of dry eye disease (DED) development. Recent studies have explored risk factors for dry eye
Researchers at the University of Illinois at Chicago have released promising results from a phase I/II clinical trial for a new enzyme-based treatment for severe dry eye.The trial compared eye drops
The near 360-degree vision of a dragonfly is providing inspiration for scientists developing artificial vision systems.After six years spent analysing dragonfly vision, Dr Russell Brinkworth and his
An international phase IIb trial of OPT-302 combination therapy for wet-AMD showed the treatment had superior results to intensive anti-VEGF-A therapy.Melbourne-based biotech company Opthea reported
